Dyne Therapeutics(DYN)
$17.99+0.07 (+0.39%)
DYN
Dyne Therapeutics financials statements
$17.99
At close:+0.07 (+0.39%)
Want to see DYN full AI Analyst Report?
Dyne Therapeutics (DYN) Ratios
489 Followers
Dyne Therapeutics Ratios
DYN's free cash flow for Q3 2026 was $-179.50M. For the 2026 fiscal year, DYN's free cash flow was decreased by $-2.01M and operating cash flow was $-177.49M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 22.25 | 15.60 | 2.53 | 9.46 | 13.31 |
| Quick Ratio | 22.25 | 15.60 | 2.53 | 9.46 | 13.31 |
| Cash Ratio | 17.65 | 10.30 | 2.38 | 6.13 | 6.99 |
| Solvency Ratio | -2.07 | -5.13 | -3.16 | -3.08 | -2.58 |
| Operating Cash Flow Ratio | -7.96 | -6.92 | -3.68 | -5.47 | -4.16 |
| Short-Term Operating Cash Flow Coverage | -80.72 | -60.28 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 911.76M | $ 597.88M | $ 55.59M | $ 211.63M | $ 324.93M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.03 | 0.17 | 0.10 | 0.08 |
| Debt-to-Equity Ratio | 0.02 | 0.04 | 0.30 | 0.12 | 0.09 |
| Debt-to-Capital Ratio | 0.02 | 0.04 | 0.23 | 0.11 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.22 | 1.10 | 1.81 | 1.21 | 1.16 |
| Debt Service Coverage Ratio | -39.15 | -64.98 | 0.00 | -58.03 | 0.00 |
| Interest Coverage Ratio | -75.61 | 0.00 | 0.00 | -58.61 | 0.00 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.21 | 0.25 | 0.46 | 0.64 | 0.64 |
| Net Debt to EBITDA | 1.99 | 1.31 | 0.40 | 0.84 | 1.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 95.31% | 92.30% | 97.43% | 98.33% | 99.51% |
| Return on Assets (ROA) | -37.59% | -45.92% | -142.92% | -54.88% | -35.07% |
| Return on Equity (ROE) | -45.90% | -50.40% | -258.44% | -66.61% | -40.55% |
| Return on Capital Employed (ROCE) | -41.20% | -52.99% | -212.45% | -61.44% | -37.80% |
| Return on Invested Capital (ROIC) | -41.02% | -52.60% | -204.00% | -60.44% | -37.43% |
| Return on Tangible Assets | -37.59% | -45.92% | -142.92% | -54.88% | -35.07% |
| Earnings Yield | -17.76% | -14.31% | -29.72% | -27.90% | -24.67% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.25 | 0.34 | 0.11 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1439.69 | -1067.82 | -3401.72 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1439.69 | 1067.82 | 3401.72 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.14 | -3.11 | -3.15 | -2.96 | -2.35 |
| Free Cash Flow Per Share | -3.15 | -3.13 | -3.16 | -3.02 | -2.42 |
| Dividend Paid and CapEx Coverage Ratio | -210.00 | -123.05 | -258.10 | -50.10 | -33.05 |
| Capital Expenditure Coverage Ratio | -210.00 | -123.05 | -258.10 | -50.10 | -33.05 |
| Operating Cash Flow Coverage Ratio | -19.88 | -12.19 | -6.86 | -5.04 | -3.66 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -16.13% | -13.29% | -23.80% | -26.01% | -20.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.64 | -6.99 | -3.36 | -3.58 | -4.05 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.58 | 3.52 | 8.70 | 2.39 | 1.64 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.20 | -7.53 | -4.20 | -3.84 | -4.91 |
| Price-to-Operating Cash Flow Ratio | -6.23 | -7.59 | -4.22 | -3.92 | -5.06 |
| Price-to-Earnings Growth (PEG) Ratio | -1.90 | 0.48 | -0.15 | -0.35 | -0.03 |
| Enterprise Value Multiple | -3.74 | -5.73 | -3.00 | -2.72 | -2.93 |
| Enterprise Value | 1.64B | 1.81B | 699.58M | 460.74M | 436.95M |
| EV to EBITDA | -3.74 | -5.73 | -3.00 | -2.72 | -2.93 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.05 | -6.13 | -3.70 | -2.94 | -3.55 |
| EV to Operating Cash Flow | -4.07 | -6.18 | -3.72 | -3.00 | -3.65 |
| Tangible Book Value Per Share | 7.57 | 6.69 | 1.53 | 4.86 | 7.23 |
| Shareholders’ Equity Per Share | 7.57 | 6.69 | 1.53 | 4.86 | 7.23 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.00 | 1.00 | 0.98 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.90 | 0.92 | 0.80 | 0.91 | 0.80 |
Currency in USD
